
Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.
Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.
Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.

Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.